Physician profile
Mark E Swetz
NPI 1013918879
$5,923.73
in general payments reported to CMS, 2019-2025
29 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,744 · 2020: $1,041 · 2021: $803 · 2022: $736 · 2023: $734 · 2024: $659 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,282.09 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $600.72 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $513.16 | 2019-2024 | Xarelto |
| Pfizer INC. | $438.65 | 2019-2025 | |
| Exact Sciences Corporation | $387.75 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $361.61 | 2020-2024 | Vraylar |
| Merck Sharp & Dohme LLC | $298.27 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $276.48 | 2019-2024 | |
| Glaxosmithkline, LLC. | $209.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $153.27 | 2019-2022 | |
| Lilly USA, LLC | $145.90 | 2019-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $117.78 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.49 | 2019 | |
| Amarin Pharma, INC. | $66.58 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $56.23 | 2019-2023 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $54.99 | 2019 | |
| Zyla Life Sciences, INC. | $54.61 | 2019 | |
| Eisai INC. | $45.15 | 2021 | |
| Currax Pharmaceuticals LLC | $40.84 | 2021 | |
| Paratek Pharmaceuticals, INC. | $40.08 | 2022-2025 | Nuzyra |
| Sanofi Pasteur INC. | $34.34 | 2019-2020 | |
| Genentech USA, INC. | $32.09 | 2020 | |
| Esperion Therapeutics, INC. | $29.28 | 2020 | |
| Daiichi Sankyo INC. | $22.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.65 | 2022 | |
| Dexcom, INC. | $18.32 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.82 | 2025 | Caplyta |
| Upsher-Smith Laboratories LLC | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Swetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.